National Cancer Institute; Notice of Meeting, 46259 [2021-17742]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices
global disease burden is hampered by
remarkably high treatment costs and a
high number of undiagnosed infections.
Moreover, a significant number of
patients develop resistance and
additional treatment modalities may be
needed to dramatically reduce the
worldwide incidence of HCV infection.
The subject cell line may be a useful
tool for studying the mechanism of HCV
cellular entry and replication and could
be incorporated into an in vitro assay to
measure the effectiveness of novel HCV
targeted therapies or as a system for
improved propagation of HCV in
culture.
By overexpressing TACSTD2 in
Huh7.5 cells, scientists at the National
Institute of Allergy and Infectious
Diseases (NIAID) discovered that they
could restore the cellular localization of
two host cell HCV-entry factors that
become dysregulated in hepatocellular
carcinoma (HCC) cells. Overexpression
of TACSTD2 makes Huh7.5 cells more
broadly permissive to infection and
replication by multiple HCV genotypes
in comparison to the canonical Huh7.5
cell model. HCV does not replicate in
malignant HCC cells, possibly caused in
part by downregulation of TACSTD2
expression.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
• Cell line to study hepatitis C virus
infection and replication or propagate
HCV in culture.
• Cell line to study cancer.
jbell on DSKJLSW7X2PROD with NOTICES
Development Stage
• Material.
Inventors: Patrizia Farci and Vandana
Sekhar (NIAID).
Publication: Sekhar V, Pollicino T,
Diaz G, Engle RE, Alayli F, Melis M,
Kabat J, Tice A, Pomerenke A, AltanBonnet N, Zamboni F, Lusso P, Emerson
SU, and Farci P. (2018) Infection with
hepatitis C virus depends on TACSTD2,
a regulator of claudin-1 and occludin
highly downregulated in hepatocellular
carcinoma. PLoS Pathog 14: e1006916.
doi: 10.1371/journal.ppat.1006916.
Licensing Contact: To license this
technology, please contact Elizabeth
Pitts, Ph.D., 240–669–5299;
elizabeth.pitts@nih.gov, and reference
E–040–2020.
Dated: August 12, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–17687 Filed 8–17–21; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:34 Aug 17, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual
meeting and is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting
should notify the Contact Person listed
below in advance of the meeting. The
meeting will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: August 31, 2021.
Open: 1:00 p.m. to 3:10 p.m.
Agenda: NCAB Subcommittee Meetings—
Subcommittee on Planning and Budget and
Ad Hoc Subcommittee on Global Cancer
Research.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Name of Committee: National Cancer
Advisory Board.
Date: September 1, 2021.
Open: 1:00 p.m. to 4:15 p.m.
Agenda: Director’s and Program reports
and presentations; business of the Board.
Closed: 4:25 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
46259
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda and any
additional information for the meetings will
be posted when available.
This notice is being published less than 15
days prior to the meeting due to scheduling
difficulties.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 13, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–17742 Filed 8–17–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Nursing Research.
The meeting will be open to the
public as indicated below via videocast.
The URL link to this meeting is https://
videocast.nih.gov/watch=42425.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
Date: September 14, 2021.
Open: 11:00 a.m. to 3:30 p.m.
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 86, Number 157 (Wednesday, August 18, 2021)]
[Notices]
[Page 46259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17742]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual meeting and is open to the
public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting should notify the Contact Person listed below in
advance of the meeting. The meeting will be videocast and can be
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: August 31, 2021.
Open: 1:00 p.m. to 3:10 p.m.
Agenda: NCAB Subcommittee Meetings--Subcommittee on Planning and
Budget and Ad Hoc Subcommittee on Global Cancer Research.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Name of Committee: National Cancer Advisory Board.
Date: September 1, 2021.
Open: 1:00 p.m. to 4:15 p.m.
Agenda: Director's and Program reports and presentations;
business of the Board.
Closed: 4:25 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm, where an agenda and any additional information for
the meetings will be posted when available.
This notice is being published less than 15 days prior to the
meeting due to scheduling difficulties.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: August 13, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-17742 Filed 8-17-21; 8:45 am]
BILLING CODE 4140-01-P
